Replies to post #161874 on Biotech Values

[DewDiligence]

New data Sunday afternoon—see next post.

[DewDiligence]

MRK is boldly testing Lambrolizumab* head-to-head vs BMY’s Yervoy in a phase-3 trial in advanced melanoma:

http://www.clinicaltrials.gov/ct2/show/NCT01866319

The primary endpoint is PFS, for which results are expected in Apr 2014. Unfortunately, the trial is open-label because the dosing intervals of the two drugs do not match.

*A/k/a MK-3475.